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While the wild type form of p53 possesses 
strong tumor-suppressive activities, the p53 
proteins that are commonly mutated in can-
cer often endow more malignant proper-
ties to the cancers they inhabit.1,2 There are 
several lines of evidence supporting such 
oncogenic gain of function of mutant p53. 
Compared with p53-null mice, knock-in mice 
harboring mutant p53 proteins display dif-
ferent and more metastatic tumor spectra. 
Such mutant proteins are frequently pres-
ent at far higher levels than the wild-type 
protein in tumors; in fact, the p53 protein 
present in the knock-in mice accumulates 
in tumors despite being inherently unstable 
in normal tissues,3 suggesting that stabiliza-
tion of mutant p53 protein is required for its 
oncogenic activity. Consistently, knockdown 
of mutant p53 protein in human cancer cell 
lines leads to reduced cell proliferation, inva-
sion, motility, tumorigenicity and resistance 
to anticancer drugs.1,2 Since epidemiological 
studies indicate that high levels of mutant 
p53 proteins correlate with tumor aggressive-
ness and poorer outcomes, it is important to 
understand how mutant p53 is stabilized in 
tumors and how it can be eliminated.
The Avantaggiati group in a recent issue 
of Cell Cycle have recently provided impor-
tant new insight into this question.4 They 
demonstrated that glucose restriction (GR) 
results in deacetylation and destabilization of 
endogenous mutant p53, but not of wild-type 
p53 protein. As protein degradation is medi-
ated primarily by two pathways; the 26S pro-
teasome and autophagy, the authors sought 
to identify which pathway is responsible for 
the degradation. They found that while the 
proteasome inhibitor MG132 treatment does 
not abolish GR-induced mutant p53 degrada-
tion, knockdown of autophagy genes such as 
Beclin-1, ATG5, ATG7 or pharmacological inhi-
bition of autophagy prevents the degradation. 
Further, mutant p53 physically interacts with 
components of the autophagy machinery in a 
GR-dependent manner, suggesting that 
mutant p53 is a substrate for autophagic 
degradation. interestingly, a C-terminal acet-
ylation-mimicking mutant version of p53 
(G245A-6KQ) is resistant to GR-dependent 
degradation. Taken together, these findings 
suggest that GR induces posttranslational 
modifications of lysines within mutant p53 
proteins, which subsequently target them for 
autophagy-dependent degradation.
The authors next examined the effects of 
GR-induced degradation of mutant p53 on 
autophagy and cancer cell death. As indicated 
by two markers of autophagy (LC3 conversion 
and p62 degradation), GR activates this pro-
cess, and the subsequent mutant p53 protein 
degradation leads to a maximal induction of 
autophagy and cell death. Consistent with 
their previous observations, expression of 
G245A-6KQ mutant p53 confers at least par-
tial resistance to GR-induced cell death. Next, 
the authors used two mutant p53 mouse 
models to investigate the effects of a low 
carbohydrate (LC) diet on p53 stability and 
tumorigenicity in vivo. in line with their ex 
vivo data, in knock-in mice harboring the 
tumor-derived p53 mutation (A135v) placed 
on an LC diet, p53 protein is destabilized in 
mammary glands, ovaries and adipose tissues, 
while p53 in wild-type mice is stabilized. in 
xenografted mice, mutant p53 expressing can-
cer cells show enhanced tumorigenicity com-
pared with those that are either p53-null or 
bearing wild-type p53.2 Strikingly, Rodriguez 
et al. found that an LC diet leads to a marked 
decrease in size of xenografted tumors with 
mutant p53, while this diet does not decrease 
tumors arising from the GR-resistant mutant 
p53G245A-6KQ expressing cells—it actually 
increases their growth.
The findings of Rodriguez et al.4 raise 
several interesting questions. First, virtually 
every residue with the ~200 amino acid DNA-
binding domain of p53 has been found to 
be mutated in different tumors, albeit with 
differing frequencies. Autophagy is acti-
vated when the proteasome fails to elimi-
nate misfolded and aggregated proteins,5 
Figure 1. Glucose restriction induces post-translational modifications of mutant p53 
(ubiquitination, Ub-mutant p53; acetylation, Ac-mutant p53), which, in turn, leads to its 
degradation by activated autophagy and ensuing autophagic cell death
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and different mutant p53 proteins vary in 
their propensity for aggregation.6 is there a 
correlation between mutant p53 proteins’ 
tendency to aggregate and their ability to be 
degraded after GR? Second, MDM2, the prime 
E3 ligase that ubiquitinates wild-type p53, 
cannot bind to p53 in Nutlin-3a-treated cells.7 
Since the authors found that while mutant 
p53 is ubiquitinated after GR, Nutlin-3a actu-
ally blocks GR-induced mutant p53 degra-
dation, what is the role of MDM2 in the 
setting of their study? Last, but not least, 
AMP-activated protein kinase (AMPK) has 
been known to regulate autophagy8 and may 
also be involved in GR-induced mutant p53 
degradation. is AMPK critical for the upstream 
signaling pathway to GR-induced mutant p53 
degradation? Answers to these and other 
questions will provide the next chapters in 
this exciting story.
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Over half a million patients are diagnosed 
with head and neck squamous cell carci-
noma (HNSCC) each year in the world. Most of 
these patients present with locally advanced 
tumors, and less than 50% will live for 5 years 
after treatment.1 Concurrent platinum-based 
chemoradiation protocols improve loco-
regional control and have become a standard 
therapeutic strategy. However, they are asso-
ciated with acute, high-grade toxicity that 
includes neutropenia, mucositis, xerostomia 
and swallowing impairment.
Consumption of alcohol and tobacco 
smoke is the major risk factor for HNSCC. 
However, compelling evidence has accumu-
lated over the last decade for infection of 
head and neck epithelium by high-risk human 
papillomaviruses (HPvs) as an emerging eti-
ology for HNSCC (about 25% of all HNSCC 
cases). The prevalence of HPv-related HNSCC 
is increasing rapidly in North America and 
North European countries. Patients with HPv-
positive tumors constitute a distinct clinical 
HNSCC subpopulation, who respond better to 
therapy and have improved relapse-free and 
overall survival.2
HPv-driven carcinogenesis is mainly a 
consequence of deregulation of the E6 and 
E7 viral oncoproteins.3 E6 binds to the p53 
tumor suppressor protein and the E6AP cel-
lular E3-ubiquitin ligase (Fig.  1A), leading to 
p53 ubiquitination, proteasomal degradation 
and impaired function. The functional conse-
quences include loss of p21-mediated control 
of the G1/S and G2/M checkpoints, reduced 
DNA-damage repair and cell cycle inhibition 
as well as decreased expression of the pro-
apoptotic Bax and Puma factors and conse-
quent diminished cell death. E7 binds to the 
Retinoblastoma protein (pRb) and induces its 
degradation (Fig.  1B). pRb inhibits cell cycle 
progression via inhibition of transcription fac-
tors of the E2F family. Loss of pRb activates 
E2F and promotes cell proliferation.
Most HPv-related HNSCC contain wild 
type TP53,4 and their better response to geno-
toxic therapies could be due to activation of 
wild-type p53. interestingly, inhibition of E6 in 
HPv-related HNSCC cell lines in culture leads 
to p53 stabilization and increases cell death.5,6 
However, there was no direct evidence that 
p53 is responsible for this effect. Proof is 
now provided by Li and Johnson.7 They have 
confirmed that inhibition of E6 and E7 by 
siRNA in HPv-positive cell lines leads to p53 
stabilization and triggers apoptotic cell death. 
in addition, they elegantly demonstrate the 
direct implication of p53 in this induced cell 
death by additional inhibition of p53. The 
authors further observe that Bortezomib, a 
proteasome-inhibitor (Fig. 1A), increases p53 
and p21 levels and results in dose-dependent 
death of HPv-positive cells. This effect is par-
tially impaired by anti-p53 siRNA treatment, 
showing that p53 is implicated to some extent 
downstream of Bortezomib. interestingly, the 
use of sublethal doses of Bortezomib leads 
to cell cycle arrest of HPv-positive cell cul-
tures at either G1 or G2/S to various extends, 
depending on the cell line. The authors pro-
vide convincing evidence that this effect is 
also dependent on both p53 and p21.
The impact of HPv on improving the sur-
vival of patients with HNSCC is now clearly 
established, and there is a debate about 
de-escalating and/or modulating standard 
therapies in order to both better manage HPv-
related HNSCC and spare patients treatment-
related toxicities. in this context, the work 
by Li and Johnson provides evidence for a 
direct role of p53 in the increased sensitivity 
of HPv-positive lesions to genotoxic agents. 
it also suggests that liberation of p53 from 
HPv E6 oncroprotein-mediated degradation, 
by inhibition of E6 or stabilization with the 
proteasome inhibitor bortezomib, could be 
interesting therapeutic options. Further work 
is required to assess the efficacy of bortezo-
mib on irradiated HPv-positive and -negative 
cell cultures. A recent phase i clinical trial 
has demonstrated that the use of bortezomid 
with concurrent cisplatin-based chemoradio-
therapy is well tolerated by HNSCC patients.8 
in the light of these new findings, it will be 
interesting to evaluate tumor response with 
respect to HPv-status
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Figure 1. Model representing the role of the 
E6 and E7 viral oncoproteins in HPv-driven 
carcinogenesis. (A) The p53 tumor suppressor 
regulates cell cycle arrest at G1 and G2/M 
and apoptosis induction via the regulation 
of its target genes, such as p21, and Puma 
and Bax respectively. HPv E6-dependent 
proteasomal degradation of p53 is blocked 
by Bortezomib. (B) pRb controls the G2/M 
cell cycle checkpoint via the inhibition of 
E2F. Binding of pRb to HPv E7 induces its 
proteasomal degradation, the activation of 
E2F and stimulation of cell proliferation.
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The primary cilium is an essential sensory 
“antenna” jutting from the cell surface of ani-
mal cells. Once thought to be a vestigial struc-
ture, the cilium has emerged in the last decade 
as a vital sensory organelle that impacts a 
broad spectrum of human diseases named 
ciliopathies.
The cilium contains a microtubule-based 
axoneme composed of nine doublet microtu-
bules arranged in a radially symmetric pattern 
that grows from the distal end of the basal 
body. The basal body is a modified centriole, a 
structural component of the centrosome that 
contains a mother-daughter centriole pair. At 
ciliogenesis, the mother matures into a basal 
body for cilium assembly. The mother centriole 
is distinguished from the daughter by distal 
and subdistal appendages that are involved 
in basal body anchoring to the membrane 
prior to cilium assembly. Loss of Cenexin1, a 
component of the distal appendages, disrupts 
cilium assembly.1 Therefore, dissecting the 
components of basal bodies and determin-
ing how they work will unravel the molecu-
lar mechanisms of ciliogenesis, providing a 
deeper understanding of ciliopathies.
Outer dense fiber protein 2 (Odf2), dis-
covered in the sperm tail cytoskeleton,2 is 
encoded by odf2, and is essential for several 
aspects of centrosome and cilium function. 
While odf2 knockout in mouse F9 cells did not 
display obvious mitotic spindle assembly or 
cell division defect, RNAi knockdown in HeLa 
cells disrupted mitotic spindle organization 
in a Polo-like kinase 1 (Plk1)-dependent man-
ner.3 Moreover, knockout mice show a very 
early pre-implantation embryonic lethality.4 
The odf2 gene encodes at least ten proteins 
by alternative splicing. Among these, at least 
two classes emerge: those that have a ~190 
amino acid C-terminal extension and those 
that do not have this domain. isoform 9, which 
has the C-terminal extension, is referred to 
as Cenexin1, whereas isoform 6, without the 
extension, is Odf2.5 This distinction is impor-
tant, because the isoforms have different func-
tions and patterns of subcellular localization. 
Odf2 is produced predominantly in the tes-
tis, where it localizes within flagella (cilia) at 
structures called outer dense fibers. Cenexin1, 
on the other hand, is a broadly expressed 
mother centriole-specific protein6 that local-
izes to the distal/subdistal appendages and is 
required for their assembly.1 These differences 
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in localization suggest diverged functions for 
the splice variants at centrosomes and cilia.
in the March 15, 2013 issue of Cell Cycle, 
Kyung Lee’s lab used mouse F9 odf2−/− knock-
out cells to show that Cenexin1, but not its 
variant Odf2, is necessary and sufficient for pri-
mary cilium assembly.5 The odf2−/− cells, which 
express no endogenous Odf2 or Cenexin1, 
are deficient in assembly of primary cilia and 
lack distal/subdistal appendages.1 Chang 
and colleagues rescued cilium assembly in 
odf2−/− cells with Cenexin1 expression, but 
not with Odf2.5 While rescue of cilium assem-
bly in odf2−/− cells was shown previously,1 the 
work from Lee’s lab shows that this function 
is specific to the Cenexin1 isoform. Regarding 
Odf2 function, work from another lab indicates 
that it is important for sperm morphogen-
esis, since about 50% of haploid sperm from 
odf2 heterozygous mutant mice have an overt 
“kinked” shape and disruption of the outer 
dense fibers.7
Consistent with the role of Cenexin1 in 
ciliogenesis, Chang and colleagues show 
that it associates with Rab8a, a small G pro-
tein required for cilium assembly, in a GTP-
dependent manner. This finding contrasts 
with a previous report that Odf2, rather than 
Cenexin1, bound to Rab8a.8 The basis of this 
contradiction is unresolved. in addition, the 
authors showed that centriolar recruitment of 
Chibby, a distal centriole protein required for 
ciliogenesis, requires Cenexin1 but not Odf2.
Chang and colleagues go on to show that 
even low expression of full-length Cenexin1, 
or a Cenexin1 mutant (S796A) defective in 
Plk1 binding could fully remedy ciliogenesis 
deficit in odf2−/− cells. However, neither Odf2 
nor Cenexin1 deleted for its C-terminal exten-
sion rescued ciliogenesis. Consistent with 
these findings, immune electron microscopy 
revealed distal/subdistal appendage localiza-
tion of Cenexin1 but not Odf2.
This study depicts a fascinating phenome-
non, where, rather than having separate genes 
encode different proteins, splice variants from 
the same gene encode distinct functions and 
localization. in this case, Cenexin1 localizes to 
distal/subdistal appendages of basal bodies, 
whereas Odf2 goes to the axoneme. Future 
findings will do doubt further illuminate the 
disparate functions of the proteins encoded 
by odf2 in centrosome and cilium biology.
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Akt destabilizes p57Kip2: Akt at the converging crossroad?
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Cell cycle progression through the G1 phase is 
tightly controlled by cyclin-dependent kinases 
(CDKs). Activity of CDKs is negatively regulated 
by two unrelated families of CDK inhibitors 
(CDKi), namely, iNK and Cip/Kip. The Cip/Kip 
family of CDKi consists of three members, 
p21Cip1/WAF1, p27Kip1 and p57Kip2. in the context 
of human cancers, these three proteins are 
considered suppressors of tumorigenesis and 
tumor progression. Therefore, their levels of 
expression in both normal and cancerous cells 
are under complex transcriptional and post-
translational regulations, including ubiquitina-
tion and proteasomal degradation.1
The upstream regulators leading to degra-
dation of p21Cip1/WAF1 and p27Kip1 proteins have 
been extensively studied. For both p21Cip1/
WAF1 and p27Kip1 proteins, Ser/Thr phosphory-
lation serves as a pivotal event that exports 
them out of nucleus and promotes their 
degradation in both cytoplasm and nucleus. 
Although multiple Ser/Thr kinases can phos-
phorylate p21Cip1/ WAF1 and p27Kip1, Akt has 
attracted substantial attention because of its 
frequent activation in many types of cancer 
and its close association with several onco-
genic receptor tyrosine kinases (RTKs), such 
as EGFR and HER2. in HER2-overexpressing 
breast cancer cells, Akt is often hyperactive 
and phosphorylates p21Cip1/WAF1 at Thr1452 and 
p27Kip1 at Thr157/Thr198,3-5 resulting in their 
nuclear export and proteasomal degradation. 
Akt-mediated destabilization of p21Cip1/WAF1 
and p27Kip1 underlies the aggressive growth 
and progression of HER2-driven breast cancer.
Emerging evidence suggests that p57Kip2 
plays an important role in embryonic devel-
opment, hematopoietic stem cell quiescence 
and inhibition of cell cycle progression. 
Unlike p21Cip1/WAF1 and p27Kip1, the upstream 
pathways leading to p57Kip2 intracellular traf-
ficking and stability are still not well under-
stood. Nevertheless, it has been reported that 
TGF-b1 stimulates p57Kip2 phosphorylation 
at Thr310, leading to its ubiquitination and 
proteasomal degradation. Stress-activated 
protein kinase p38 phosphorylates p57Kip2 at 
Thr143 and enhances p57Kip2 association with 
and inhibition of CDK2.6 Subunit 6 of the 
COP9 signalosome complex (CSN6) associ-
ates with p57Kip2 and Skp2, a component of 
the E3 ligase. This association, in turn, leads 
to Skp2-mediated p57Kip2 ubiquitination and 
subsequent degradation.7 interestingly, CSN6 
can be phosphorylated by Akt at Ser60, which 
renders CSN6 more stabilized.
The elegant study by Zhao et al. showed 
for the first time that Akt interacts with and 
phosphorylates p57Kip2 at Ser282 and Thr310, 
resulting in p57Kip2 nuclear export, ubiquiti-
nation and proteasome-mediated degrada-
tion.8 HER2-overexpressing breast cancer cells 
were found to express lower levels of p57Kip2 
than those with normal HER2 expression. 
Constitutively active Akt induced p57Kip2 deg-
radation, whereas a dominant-negative Akt 
mutant and Pi3K inhibition led to p57Kip2 stabi-
lization. The authors further showed that Akt-
mediated phosphorylation and stabilization 
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of CSN6 contributed to p57Kip2 degradation. 
Consistent with these observations, restora-
tion of p57Kip2 in HER2-amplified, p57Kip2-defi-
cient breast cancer cells led to reduced cell 
growth in vitro and the inability to form xeno-
grafts in nude mice, indicating that p57Kip2 
antagonizes HER2-mediated breast cancer cell 
growth and possibly HER2-related tumorigen-
esis. Analysis of patient breast carcinomas 
revealed for the first time that in patients with 
HER2-overexpressing tumors, low p57Kip2 levels 
correlated with poor overall survival.
A significant implication for the novel 
Ak→p57Kip2 signaling axis is that it may play 
an important role in embryonic development 
in addition to cancer. Unlike p21Cip1/WAF1 and 
p27Kip1, p57Kip2-knockout mice uniquely dis-
played developmental defects and a pheno-
type that resembles the Beckwith-Wiedeman 
syndrome, a childhood overgrowth syndrome. 
The potential involvement of the Akt→p57Kip2 
link in embryonic development is worthy of 
investigations in future studies.
in light of the new findings reported by 
Zhao et al. combined with those published 
previously,2-5 we now know that Akt phos-
phorylates all three members of the Cip/
Kip family of CDKi (Fig. 1). This important 
discovery indeed revised the signaling land-
scape for the HER2→Akt signaling module, 
in that Akt plays a central role in lifting CDKi-
mediated cell cycle arrest and therefore facili-
tates proliferation of HER2-amplified breast 
cancer. An immediate significant implication 
of these findings is that the newly discov-
ered Akt→p57Kip2 signaling axis may have a 
broad impact on different subtypes of breast 
cancers, such as triple-negative and basal-
like breast cancer, given the fact that Akt 
can also be activated by other RTKs besides 
HER2, such as EGFR, iGF-1R, vEGFR, c-Met 
and PDGFR. Another potential implication 
is that the negative regulation of p57Kip2 by 
Akt may also exist in other types of can-
cer, since Akt activation is a common phe-
nomenon in a number of human cancers. 
indeed, future investigations are needed to 
broadly explore the impact of the Akt→p57Kip2 
signaling axis on cancer and embryonic 
development.
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Figure 1. Akt at the converging crossroad connecting multiple receptor tyrosine kinases to all three 
members of the Cip/Kip family of CDKi. Akt is known to be activated by several upstream RTKs 
that are frequently activated in human cancers. These RTKs include HER2, EGFR, iGF-1R, vEGFR, 
c-Met, PDGFR and several others. it is also known that there are a number of proteins serving as 
the downstream effectors of Akt, such as, mTOR and two CDKi, p21Cip1/WAF1 and p27Kip1. importantly, 
the study by Zhao et al. provided the first evidence that defines p57Kip2 as the substrate of Akt, thus 
making Akt a central common Ser/Thr kinase that negatively regulates all three members of the 
Cip/Kip family of CDKi that contribute to cell cycle arrest. Consequently, these reported findings 
potentially place Akt at the converging point that connects multiple RTKs to all three members 
of the Cip/Kip family of CDKi, in order to unblock cell cycle arrest and support uncontrolled cell 
proliferation in cancer cells.
